Pharmaceutical regulatory data, drug approvals & compliance tracking
Home › Compliance › Biosimilar
This page provides comprehensive data and analytics for biosimilar compliance guide. Our database is updated regularly to ensure accuracy and relevance. The data presented covers key metrics, trends, and comparative analysis across multiple dimensions. Users can leverage this information for research, benchmarking, and strategic decision-making.
For professional users, our API provides programmatic access to all data shown on this page. Rate limits apply based on your subscription tier. Contact us for enterprise pricing. Regional variations can significantly impact the numbers shown. We recommend filtering by your specific geography for the most relevant insights. Our coverage spans major markets worldwide.
All data on FDA News is provided for informational purposes. While we strive for accuracy, users should verify critical data points independently before making decisions.
| Requirement | Category | Deadline | Penalty | Reference |
|---|---|---|---|---|
| Annual registration | Mandatory | Dec 31 | $15,000 | 21 CFR 207 |
| Adverse event reporting | Mandatory | 15 days | Warning letter | 21 CFR 314 |
| Label review | Pre-market | Before launch | Seizure | 21 CFR 201 |
| GMP audit | Every 2 years | Ongoing | Import alert | 21 CFR 211 |
| Record keeping | Mandatory | Ongoing | $10,000/day | 21 CFR 211 |
Data updated continuously. Last refresh: May 11, 2026 14:30 UTC.
